Research Article
Effect of Low-Dose, Long-Term Roxithromycin on Airway Inflammation and Remodeling of Stable Noncystic Fibrosis Bronchiectasis
Table 1
Demographic and baseline characteristics.
| | Parameters | Control group | Roxithromycin group | value |
| | Sex (M : F) | 21 (12 : 9) | 22 (11 : 11) | 0.157 | | Age (years) | | | 0.423 | | Body mass index | | | 0.674 | | Patient’s disease history (years) | | | 0.141 | | Smoking status | | | | | Present smokers | 3 | 5 | 0.4763 | | Smoking history (pack-years) | | | 0.2210 | | Spirometry | | | | | FEV1 (L) | | | 0.7417 | | Percentage of predicted FEV1 | | | 0.8651 | | FVC (L) | | | 0.7087 | | FEV1/FVC | | | 0.9220 | | High-resolution CT parameter | | | | | Small-airway abnormalities | | | 0.268 | | Bronchial wall thickening | | | 0.862 | | Extent of bronchiectasis | | | 0.967 | | Global CT score | | | 0.788 |
|
|
CT: computed tomography.
|
